SUMMIT, N.J.–(BUSINESS WIRE)–A new survey examines the topic of brain volume loss, known as brain atrophy, in people with multiple sclerosis. The survey findings, presented at ECTRIMS 2018, suggest that there is a high level of interest in better understanding how brain atrophy may impact disease progression. Sixty-three percent of …
Tag Archives: ECTRIMS
October, 2018
September, 2016
-
19 September
Novartis’ BAF312 Reduced the Risk of Disability Progression in Late-Stage Multiple Sclerosis Study
Basel, September 17, 2016 – Novartis today announced positive results of the Phase III EXPAND study showing that oral once-daily BAF312 (siponimod) significantly reduced the risk of disability progression compared with placebo in people with secondary progressive multiple sclerosis (SPMS).[1] SPMS is a form of MS characterized by continuous worsening …
-
15 September
New Data Reinforce Efficacy of Zinbryta and Support Long-Term Safety Profile
CAMBRIDGE, Mass. & NORTH CHICAGO, Ill.–(BUSINESS WIRE)–A new post-hoc analysis from the pivotal DECIDE study shows that a significantly greater number of people treated with ZINBRYTATM (daclizumab) achieved no evidence of disease activity (NEDA) compared to those taking AVONEX® (interferon beta-1a) intramuscular injection. The findings continue to support the positive …
-
14 September
Genentech Announces New Late-Stage Data from Three Trials of OCREVUS in MS
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche group (SIX: RO, ROG; OTCQX: RHHBY), today announced new analyses from the three OCREVUS™ (ocrelizumab) Phase III studies in relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) will be presented during the 32nd congress of the European Committee …
January, 2016
-
13 January
The MS Game Changer
A new medication for multiple sclerosis made waves when research about its effectiveness debuted at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) back in October 2015. Now experts are calling this medication one of the greatest developments of the past year for the …
October, 2015
-
7 October
Biogen’s Tecfidera Demonstrates Long-Term Efficacy in Newly-Diagnosed MS Patients
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Biogen (NASDAQ: BIIB) will present new data that reinforce the proven efficacy and well-established safety profile of TECFIDERA® (dimethyl fumarate) in a broad range of people with relapsing-remitting multiple sclerosis (RRMS) at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain …